Sinopharm Group rebounds after posting an upbeat 3Q result

feature image
Sinopharm Group (1099), a pharmaceutical company, rose around 5% after the company announced that 9-month net income grew 7.8% on year to 4.96 billion yuan on operating revenue of 327.61 billion yuan, up 4.8%.

Besides, Chinese Media reported that 4 Covid-19 Vaccines of Sinopharm are conducting the Phase III clinical tests in overseas countries.

Technically, the stock posted a rebound and broke above a declining channel. Currently, the prices stand above its 20-day moving average. The relative strength index also indicates a bullish divergence signal.

The bullish readers could set a support level at HK$16.40, while resistance levels would be HK$19.00 and HK$20.40.


Source: GAIN Capital, TradingView
Related tags: equities stocks china

Open an account in minutes

Experience award-winning platforms with fast and secure execution.

Live Trading Webinars

Our interactive webinars, led by our industry experts, come highly recommended and can help provide your trading with the edge it needs.
Economic Calendar